212 related articles for article (PubMed ID: 28456898)
1. Predictive Value of Early Skin Rash in Cetuximab-Based Therapy of Advanced Biliary Tract Cancer.
Rubovszky G; Budai B; Ganofszky E; Horváth Z; Juhos É; Madaras B; Nagy T; Szabó E; Pintér T; Tóth E; Nagy P; Láng I; Hitre E
Pathol Oncol Res; 2018 Apr; 24(2):237-244. PubMed ID: 28456898
[TBL] [Abstract][Full Text] [Related]
2. A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.
Chen JS; Hsu C; Chiang NJ; Tsai CS; Tsou HH; Huang SF; Bai LY; Chang IC; Shiah HS; Ho CL; Yen CJ; Lee KD; Chiu CF; Rau KM; Yu MS; Yang Y; Hsieh RK; Chang JY; Shan YS; Chao Y; Chen LT;
Ann Oncol; 2015 May; 26(5):943-949. PubMed ID: 25632066
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.
Rubovszky G; Láng I; Ganofszky E; Horváth Z; Juhos E; Nagy T; Szabó E; Szentirmay Z; Budai B; Hitre E
Eur J Cancer; 2013 Dec; 49(18):3806-12. PubMed ID: 24007821
[TBL] [Abstract][Full Text] [Related]
4. Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer.
Park K; Kim KP; Park S; Chang HM
Asia Pac J Clin Oncol; 2017 Feb; 13(1):13-20. PubMed ID: 27770489
[TBL] [Abstract][Full Text] [Related]
5. PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.
Vogel A; Kasper S; Bitzer M; Block A; Sinn M; Schulze-Bergkamen H; Moehler M; Pfarr N; Endris V; Goeppert B; Merx K; Schnoy E; Siveke JT; Michl P; Waldschmidt D; Kuhlmann J; Geissler M; Kahl C; Evenkamp R; Schmidt T; Kuhlmann A; Weichert W; Kubicka S
Eur J Cancer; 2018 Mar; 92():11-19. PubMed ID: 29413685
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.
Gruenberger B; Schueller J; Heubrandtner U; Wrba F; Tamandl D; Kaczirek K; Roka R; Freimann-Pircher S; Gruenberger T
Lancet Oncol; 2010 Dec; 11(12):1142-8. PubMed ID: 21071270
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
9. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.
Khan K; Cunningham D; Peckitt C; Barton S; Tait D; Hawkins M; Watkins D; Starling N; Rao S; Begum R; Thomas J; Oates J; Guzzardo V; Fassan M; Braconi C; Chau I
Oncotarget; 2016 Mar; 7(11):12672-81. PubMed ID: 26862857
[TBL] [Abstract][Full Text] [Related]
10. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues.
Brieau B; Dahan L; De Rycke Y; Boussaha T; Vasseur P; Tougeron D; Lecomte T; Coriat R; Bachet JB; Claudez P; Zaanan A; Soibinet P; Desrame J; Thirot-Bidault A; Trouilloud I; Mary F; Marthey L; Taieb J; Cacheux W; Lièvre A
Cancer; 2015 Sep; 121(18):3290-7. PubMed ID: 26052689
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
12. Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial.
Zhang X; Xu J; Liu H; Yang L; Liang J; Xu N; Bai Y; Wang J; Shen L
Med Oncol; 2014 Oct; 31(10):226. PubMed ID: 25234930
[TBL] [Abstract][Full Text] [Related]
13. Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers.
Ogul A; Kidi MM; Buyuksimsek M
J Gastrointest Cancer; 2021 Mar; 52(1):294-299. PubMed ID: 32495108
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.
Feng K; Liu Y; Zhao Y; Yang Q; Dong L; Liu J; Li X; Zhao Z; Mei Q; Han W
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487569
[TBL] [Abstract][Full Text] [Related]
15. Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology.
Borbath I; Ceratti A; Verslype C; Demols A; Delaunoit T; Laurent S; Deleporte A; Vergauwe P; Van Maanen A; Sempoux C; Van Cutsem E; Van Laethem JL;
Ann Oncol; 2013 Nov; 24(11):2824-9. PubMed ID: 23975665
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
17. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
Arima S; Shimizu K; Okamoto T; Toki M; Suzuki Y; Okano N; Naruge D; Kawai K; Kobayashi T; Kasuga A; Kitamura H; Takasu A; Nagashima F; Sugiyama M; Furuse J
Anticancer Res; 2017 Feb; 37(2):909-914. PubMed ID: 28179351
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.
Irigoyen A; Gallego J; Guillén Ponce C; Vera R; Iranzo V; Ales I; Arévalo S; Pisa A; Martín M; Salud A; Falcó E; Sáenz A; Manzano Mozo JL; Pulido G; Martínez Galán J; Pazo-Cid R; Rivera F; García García T; Serra O; Fernández Parra EM; Hurtado A; Gómez Reina MJ; López Gomez LJ; Martínez Ortega E; Benavides M; Aranda E;
Eur J Cancer; 2017 Apr; 75():73-82. PubMed ID: 28222309
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease.
Lamarca A; Benafif S; Ross P; Bridgewater J; Valle JW
Eur J Cancer; 2015 Sep; 51(13):1694-703. PubMed ID: 26066735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
